Longer-term outcomes of letrozole versus placebo after 5 years of tamoxifen in the NCIC CTG MA.17 trial: Analyses adjusting for treatment crossover

Journal of Clinical Oncology

Volumn 30, Issue 7, 2012, Pages 718-721

  Jin, Huan ^a   Tu, Dongsheng ^b   Zhao, Naiqing ^a   Shepherd, Lois E ^b   Goss, Paul E ^c  

^a FUDAN UNIVERSITY   (China)

^b QUEEN S UNIVERSITY   (Canada)

^c MASSACHUSETTS GENERAL HOSPITAL CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

LETROZOLE; PLACEBO; TAMOXIFEN;

ARTICLE; BREAST CANCER; CLINICAL ASSESSMENT; DISEASE FREE SURVIVAL; DRUG EFFICACY; FOLLOW UP; HUMAN; INVERSE PROBABILITY OF CENSORING WEIGHTED MODEL; LONG TERM CARE; MEDICAL RESEARCH; OVERALL SURVIVAL; PATIENT COMPLIANCE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); TREATMENT OUTCOME;

AROMATASE INHIBITORS; BREAST NEOPLASMS; DISEASE-FREE SURVIVAL; DOUBLE-BLIND METHOD; DRUG ADMINISTRATION SCHEDULE; FEMALE; HUMANS; MIDDLE AGED; NITRILES; PLACEBOS; POSTMENOPAUSE; TAMOXIFEN; TREATMENT OUTCOME; TRIAZOLES;

EID: 84857567970     PISSN: 0732183X     EISSN: 15277755     Source Type: Journal    
DOI: 10.1200/JCO.2010.34.4010     Document Type: Article

References (13)

1. Goss PE, Ingle JN, Martino S, et al: A randomized trial of letrozole in postmenopausal women after five years of tamoxifen therapy for early-stage breast cancer. N Engl J Med 349:1793-1802, 2003 (Pubitemid 37362955)
2. Goss PE, Ingle JN, Martino S, et al: Randomized trial of letrozole following tamoxifen as extended adjuvant therapy in receptor-positive breast cancer: Updated findings from NCIC CTG MA.17. J Natl Cancer Inst 97:1262-1271, 2005 (Pubitemid 41535367)
3. Ingle JN, Tu D, Pater JL, et al: Intent-to-treat analysis of the placebo-controlled trial of letrozole for extended adjuvant therapy in early breast cancer: NCIC CTG MA.17. Ann Oncol 19:877-882, 2008 (Pubitemid 351627301)
4. Goss PE, Ingle JN, Pater JL, et al: Late extended adjuvant treatment with letrozole improves outcome in women with early-stage breast cancer who complete 5 years of tamoxifen. J Clin Oncol 26:1948-1955, 2008
5. Sommer A, Zeger SL: On estimating efficacy from clinical trials. Stat Med 10:45-52, 1991
6. Korn EL, Freidlin B: Causal inference for definitive clinical end points in a randomized clinical trial with intervening nonrandomized treatments. J Clin Oncol 28:3800-3802, 2010
7. BIG 1-98 Collaborative Group, Mouridsen H, Giobbie-Hurder A, et al: Letrozole therapy alone or in sequence with tamoxifen in women with breast cancer. N Engl J Med 361:766-776, 2009
8. Colleoni M, Giobbie-Hurder A, Regan MM, et al: Analyses adjusting for selective crossover show improved overall survival with adjuvant letrozole compared with tamoxifen in the BIG 1-98 study. J Clin Oncol 29:1117-1124, 2011
9. Finkelstein DM, Schoenfeld DA: Correcting for discretionary treatment crossover in an analysis of survival in the Breast International Group BIG 1-98 trial by using the inverse probability of censoring weighted method. J Clin Oncol 29:1093- 1095, 2011
10. Shao J, Chang M, Chow SC: Statistical inference for cancer trials with treatment switching. Stat Med 24:1783-1790, 2005 (Pubitemid 40872642)
11. Robins JM, Finkelstein DM: Correcting for noncompliance and dependent censoring in an AIDS Clinical Trial with inverse probability of censoring weighted (IPCW) log-rank tests. Biometrics 56:779-788, 2000
12. D'Agostino RB, Lee ML, Belanger AJ, et al: Relation of pooled logistic regression to time dependent Cox regression analysis: The Framingham Heart Study. Stat Med 9:1501-1515, 1990
13. White IR: Estimating treatment effects in randomized trials with treatment switching. Stat Med 25:1619-1622, 2006